Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3622257 | 0.82 | SMN1; SMN2 (0.52) | RAB9ANPC1SMN1; SMN2POLBMAPT | |
| SCHEMBL12756834 | 0.82 | RAB9A (0.44) | RAB9ANPC1SMN1; SMN2POLBMAPT | |
| SCHEMBL1954783 | 0.80 | HCAR2 (0.57) | RAB9ANPC1SMN1; SMN2POLBMAPT | |
| SCHEMBL1954102 | 0.79 | ANO1 (0.61) | SMN1; SMN2HTTMEN1KMT2AALDH1A1 | |
| SCHEMBL1954819 | 0.79 | MEN1 (0.56) | RAB9ANPC1SMN1; SMN2POLBMAPT | |
| SCHEMBL7955092 | 0.79 | KMT2A (0.52) | RAB9ANPC1SMN1; SMN2POLBMAPT | |
| SCHEMBL1954139 | 0.79 | SMN1; SMN2 (0.67) | RAB9ANPC1SMN1; SMN2POLBMAPT | |
| SCHEMBL3628782 | 0.78 | MEN1 (0.49) | RAB9ANPC1SMN1; SMN2POLBHTT | |
| SCHEMBL12271094 | 0.77 | HCAR2 (0.54) | RAB9ANPC1SMN1; SMN2POLBMAPT | |
| SCHEMBL1952421 | 0.77 | SMN1; SMN2 (0.49) | RAB9ANPC1SMN1; SMN2POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231344-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231344-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-8372991-B2 | Trisubstituted thiophenes that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372991-B2 | Trisubstituted thiophenes that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-7981925-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981925-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20110166159-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166159-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20100056532-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056532-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| WO-2010025295-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231344-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | RAB9A 1174/4885NPC1 262/4885SMN1; SMN2 854/4885 |
| US-20110166159-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | RAB9A 1174/4885NPC1 262/4885SMN1; SMN2 854/4885 |
| US-20100056532-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | RAB9A 1174/4885NPC1 262/4885SMN1; SMN2 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.